Efficacy and safety of tucatinib (TUC) vs placebo (PBO) combined with trastuzumab and pertuzumab (HP) as maintenance therapy for HER2+ metastatic breast cancer by stratified subgroups.

Erika P. Hamilton; G Curigliano; Casado Martín M; Florence Lerebours; Junji Tsurutani; Marie-France Savard; Xichun Hu; Luciana Carla Martins de Aquino; Ciara Catherine O'Sullivan; Eriko Tokunaga; Alicia Frances Clare Okines; Chiun-Sheng Huang; W Jacot; J Sohn; Volkmar Mueller; Helene Viala; Qianwen Tan; Wentao Feng; Qi Shen; V Dieras

doi:10.1200/jco.2026.44.16_suppl.1005

Key Points

To evaluate the efficacy and safety of tucatinib combined with trastuzumab and pertuzumab for maintaining HER2+ metastatic breast cancer treatment.
Phase 3 HER2CLIMB-05 study, NCT05132582
Patients with confirmed HER2+ metastatic breast cancer randomly assigned to tucatinib or placebo plus HP
Primary endpoint of progression-free survival assessed by investigators.
Median progression-free survival (PFS) was significantly longer with tucatinib (24.9 months) compared to placebo plus HP (16.3 months), HR 0.641, P<0.0001.
Confirmed objective response rate (cORR) was 22.6% for tucatinib and 15.2% for placebo, indicating superior efficacy.
Safety outcomes were consistent across subgroups with no new safety signals identified.

No abstract yet

We only have this paper's title and publication details.

Read it at the source

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Randomized trial demonstrates improved outcomes in HER2+ metastatic breast cancer with Tucatinib maintenance therapy, suggesting efficacy across diverse subgroups.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Hamilton et al. (2026) studied this question.

synapsesocial.com/papers/6a192de6fab5b468c4416eaa https://doi.org/10.1200/jco.2026.44.16_suppl.1005

View at Publisher

Ask AI

Bookmark

Share

Efficacy and safety of tucatinib (TUC) vs placebo (PBO) combined with trastuzumab and pertuzumab (HP) as maintenance therapy for HER2+ metastatic breast cancer by stratified subgroups.

Key Points

No abstract yet

Ask about this paper

Implication

Discussion

Cite This Study

Efficacy and safety of tucatinib (TUC) vs placebo (PBO) combined with trastuzumab and pertuzumab (HP) as maintenance therapy for HER2+ metastatic breast cancer by stratified subgroups.

Key Points

No abstract yet

Ask about this paper

Implication

Discussion

Cite This Study

Keep reading

Keep reading